FounderNest™

Start exploring your own markets for free

🚀 Try for Free

/AI Therapeutics

Invite

Pending to review

Not sure yet

Interested

Not interested

Download list

Company	Fit assessment	Description	Subspaces	Tags	HQ Location	Founding Date	Employees	Total Funding Raised	Last Funding Event	Received on
Rosetta Omics	The company effectively leverages machine learning for biomarker identification and the development of new therapeutic strategies, enhancing personalized medicine in oncology.	Operator of a biotechnology company intended to unlock the road to precision medicine in oncology by tumor characterization via high-resolution proteomic profiling via the combined use of mass spectrometry imaging and machine learning algorithms. The company focuses on personalized medicine by offering patients the right treatment at the right time, especially for poor prognosis cancers like digestive cancers, enabling better patient management and saving billions of money for the healthcare systems.	Biomarker Identification	Light Search	Paris (France)	2022	1 - 10		Non-Equity Assistance, May 1, 2024	Oct 14, 2024
Javelin Biotech	Javelin Biotech effectively leverages machine learning and pattern discovery to enhance drug discovery and expand therapeutic options.	Javelin Biotech is a framework for predictive drug discovery designed to improve drug performance prediction in humans. The company's platform enables biopharmaceutical companies to optimize ADME(T) and PD properties, which improve drug discovery and approval of the same, by bringing human-relevant in-vitro data and computational biology or data analytics to pre-clinical drug discovery teams. This accelerates preclinical drug discovery and development by finding human-relevant targets.	Drug Discovery Optimization	Light Search	Woburn (United States)	2018	11 - 50		Pre-Seed, January 1, 2019	Oct 14, 2024
Quibim	Quibim is a leader in medical imaging analysis, utilizing AI to enhance the detection of diseases and track treatment efficacy through quantitative imaging biomarkers. Their platform integrates multi-omics data and advanced algorithms to improve patient outcomes in various medical fields, including oncology and immunology.	Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading pharmaceutical companies and research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human.	Biomarker Identification	Light Search	Valencia (Spain)	2012	51 - 200	$69.59M	Series A, $50.00M, January 28, 2025	Oct 14, 2024
Yunjian	Yunjian leverages machine learning and big data to discover disease markers and expand therapeutics, demonstrating a strong fit for the requirements.	Yunjian is a new generation of metabolomics- and protein-based marker-finding technologies. has developed a distinctive analytic platform based on mass spectrometry proteomics and big data, driven by medical theories that greatly reduce the time required by conventional methods to find disease markers. has a wealth of experience in big data illness models, medication development, disease biomarker identification, clinical translation and diagnostics, and data security.	Biomarker Identification	Light Search	Hangzhou (China)	2015	11 - 50	$1.29M	Series B, August 19, 2022	Oct 14, 2024
Flagship Biosciences	Flagship Biosciences leverages machine learning for data analysis, discovers new patterns in biomarker data, and supports drug development, enhancing therapeutic options.	Flagship Biosciences delivers comprehensive tissue profiling for predictive diagnostic applications using our Artificial Intelligence (AI) enabled cTA® pathology platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients.	Biomarker Identification	Light Search	Westminster (United States)	2009	51 - 200	$20.29M	Venture - Series Unknown, $5.00M, April 16, 2024	Oct 14, 2024
Meliora Therapeutics	Meliora Therapeutics leverages machine learning to discover new drug mechanisms and expand therapeutic options, optimizing the drug discovery process.	Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications.	Drug Discovery Optimization	Light Search	San Francisco (United States)	2021	11 - 50	$11.00M	Seed, $11.00M, September 29, 2022	Oct 14, 2024
DeepThink Health	DeepThink Health leverages machine learning to discover patterns and expand therapeutics, while effectively analyzing genomic data.	DeepThink Health has developed a precision intelligence platform that collects, structures, organizes and curates genomic, clinical and lifestyle patient data, and then turns it into actionable intelligence. Its technology platform transforms real-world data into intelligence using DeepThink's advanced analytics, artificial intelligence (AI), predictive modeling, natural language processing and other machine learning tools. This intelligence is used by clinicians, researchers and others to improve patient outcomes, lower institutional costs, and make novel discoveries in the advancement of healthcare. DeepThink Health's innovative team has decades of experience in clinical workflows, data interoperability, big data analytics and artificial intelligence.	Genomic Data Analysis	Light Search	Richmond (United States)	2018	11 - 50		NA	Oct 14, 2024
converger.ai	Converger.ai leverages machine learning and data analytics to discover patterns in genetics and expand therapeutic approaches for disease prevention and treatment.	We are a biotechnology company that uses novel analytics to unlock the secrets of human genetic diversity, helping prevent, diagnose and treat disease.	Genomic Data Analysis	Light Search	Johannesburg (South Africa)	2023	1 - 10	$205.13K	Pre-Seed, $200.00K, June 20, 2023	Oct 14, 2024
AliveX	AliveX effectively utilizes machine learning for pattern discovery and therapeutic expansion, with a strong focus on biomarker identification.	Application of artificial intelligence, multi-omics data, and digital disease models to enable the next era of target & biomarker R&D.	Biomarker Identification	Light Search	Zürich (Switzerland)	2019	51 - 200		Seed, June 22, 2021	Oct 14, 2024
BioAI Health	BioAI Health effectively utilizes machine learning for pattern discovery and therapeutic expansion, focusing on biomarker identification to enhance personalized medicine.	BioAI Health is a biotech company that uses AI to improve disease diagnosis and predict patient response to therapy. Its platform technology integrates complex data sets from translational studies and clinical trials. It has the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy and drug resistance. The company was founded in 2020 and is based in Goffstown, New Hampshire.	Biomarker Identification	Light Search	Goffstown (United States)	2020	11 - 50	$3.50M	Seed, $500.00K, April 9, 2024	Oct 14, 2024

Use "Get more companies" to continue searching, or run a “Deep Dive” for a comprehensive mapping